Cosentyx
Sponsors
Mayo Clinic, Assistance Publique - Hôpitaux de Paris, Janssen Research & Development, LLC, Novartis Pharmaceuticals
Conditions
Autoimmune DiseasesHealthyInflammatory DiseaseModerate to Severe Chronic Plaque PsoriasisPITYRIASIS RUBRA PILARISPsoriasis VulgarisPsoriatic ArthritisPustular Psoriasis
Phase 1
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
CompletedNCT03342573
Start: 2018-04-01End: 2022-02-01Updated: 2022-02-24
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
CompletedNCT04589026
Start: 2020-10-21End: 2021-05-06Updated: 2025-02-03
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
CompletedNCT05522517
Start: 2022-08-22End: 2022-11-02Updated: 2025-02-03
Phase 2
Unknown Phase
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
CompletedNCT05215561
Start: 2022-02-14End: 2024-09-28Updated: 2025-06-08
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
CompletedNCT05388916
Start: 2022-09-08End: 2025-02-27Updated: 2025-12-29